LivaNova, PLC, reports the first implant of the Perceval sutureless valve in the PERSIST-AVR (Perceval Sutureless Implant Vs Standard Aortic Valve Replacement) trial. Perceval is a sutureless heart valve for patients who require replacement of their aortic valve.
With more than 115 publications behind it, the Perceval sutureless valve has already been implanted in more than 15,000 patients in over 310 hospitals worldwide.
PERSIST-AVR is the first worldwide, prospective, randomized, multi-center trial, comparing Perceval sutureless aortic valve with standard sutured bioprostheses in patients with aortic valve disease. The study will enroll over 1,200 patients with severe symptomatic aortic stenosis or steno-insufficiency in patients who are candidates for surgical replacement of their native aortic valve. The primary endpoint of the trial is non-inferiority of Major Adverse Cardiac Cerebrovascular Events (MACCE) at one year according to VARC-2 criteria.
The study is planned to have a two-year enrollment period and a yearly follow-up for a five-year period with the primary endpoint expected to be available in 2019.
The newly reported procedure was enrolled by Professor Thierry Folliguet, M.D., Ph.D at CHU Brabois, University of Lorraine, Nancy, France. Professor Folliguet is part of the Steering Committee of the study and one of the early implanters of Perceval.
“The clinical experience with the Perceval valve has been positive on multiple fronts as measured by reduced cross-clamp time, great hemodynamic performance, low structural valve deterioration and freedom from reoperation up to five-year follow-up.2 PERSIST-AVR is designed to confirm these results compared to standard sutured stented valves. Moreover, the trial will demonstrate how the use of Perceval in aortic valve surgery is linked with significant cost savings, driven primarily by reduced procedural costs and reduced hospital stay,” said Professor Folliguet. “We know that PERSIST-AVR is a landmark clinical trial, being the first randomized study in 30 years in the field of valvular surgery. Its initiation is a great endeavor in the cardiac surgery communities. More than 60 centers around the world will be recruited pointing out the strong interest generated by Perceval. We look forward to obtaining promising data for the use of Perceval in the daily aortic valve replacement setting,” said Professor Theodor Fischlein, M.D., Ph.D., Paracelsus Medical University Cardiovascular Center, Nuremberg, Germany, and Dr. Roberto Lorusso, M.D., Ph.D., Cardio-Thoracic Surgery Department, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands, both principal investigators of the study.
“As the first trial of its kind, the PERSIST-AVR study is a significant milestone for LivaNova, the healthcare community and patients worldwide,” said Michel Darnaud, President, Cardiac Surgery B.U., LivaNova, PLC. “We are proud to support this important trial. We anticipate its results could significantly impact daily practice and establish the Perceval sutureless valve as the prosthesis of choice for future heart valve surgeries.”
Source: Globe Newswire